Literature DB >> 25833819

Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain.

Nicole Maphis1, Guixiang Xu2, Olga N Kokiko-Cochran2, Shanya Jiang1, Astrid Cardona3, Richard M Ransohoff4, Bruce T Lamb2, Kiran Bhaskar5.   

Abstract

Pathological aggregation of tau is a hallmark of Alzheimer's disease and related tauopathies. We have previously shown that the deficiency of the microglial fractalkine receptor (CX3CR1) led to the acceleration of tau pathology and memory impairment in an hTau mouse model of tauopathy. Here, we show that microglia drive tau pathology in a cell-autonomous manner. First, tau hyperphosphorylation and aggregation occur as early as 2 months of age in hTauCx3cr1(-/-) mice. Second, CD45(+) microglial activation correlates with the spatial memory deficit and spread of tau pathology in the anatomically connected regions of the hippocampus. Third, adoptive transfer of purified microglia derived from hTauCx3cr1(-/-) mice induces tau hyperphosphorylation within the brains of non-transgenic recipient mice. Finally, inclusion of interleukin 1 receptor antagonist (Kineret®) in the adoptive transfer inoculum significantly reduces microglia-induced tau pathology. Together, our results suggest that reactive microglia are sufficient to drive tau pathology and correlate with the spread of pathological tau in the brain.
© The Author (2015). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Alzheimer’s disease; microglia; neuroinflammation; tau protein; tauopathies

Mesh:

Substances:

Year:  2015        PMID: 25833819      PMCID: PMC4542622          DOI: 10.1093/brain/awv081

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  73 in total

Review 1.  Microglia in neurodegeneration: molecular aspects.

Authors:  P J Gebicke-Haerter
Journal:  Microsc Res Tech       Date:  2001-07-01       Impact factor: 2.769

2.  Effect of proinflammatory gene polymorphisms on the risk of Alzheimer's disease.

Authors:  Andrea Flex; Silvia Giovannini; Federico Biscetti; Rosa Liperoti; Gianfranco Spalletta; Giuseppe Straface; Francesco Landi; Flavia Angelini; Carlo Caltagirone; Giovanni Ghirlanda; Roberto Bernabei
Journal:  Neurodegener Dis       Date:  2013-09-06       Impact factor: 2.977

3.  Interleukin-1 promotion of MAPK-p38 overexpression in experimental animals and in Alzheimer's disease: potential significance for tau protein phosphorylation.

Authors:  J G Sheng; R A Jones; X Q Zhou; J M McGinness; L J Van Eldik; R E Mrak; W S Griffin
Journal:  Neurochem Int       Date:  2001 Nov-Dec       Impact factor: 3.921

4.  Expression of inflammatory genes in the primary visual cortex of late-stage Alzheimer's disease.

Authors:  Jian-Guo Cui; James M Hill; Yuhai Zhao; Walter J Lukiw
Journal:  Neuroreport       Date:  2007-01-22       Impact factor: 1.837

5.  Microglial activation in brain lesions with tau deposits: comparison of human tauopathies and tau transgenic mice TgTauP301L.

Authors:  Atsushi Sasaki; Takeshi Kawarabayashi; Tetsuro Murakami; Etsuro Matsubara; Masaki Ikeda; Haruo Hagiwara; David Westaway; Peter S George-Hyslop; Mikio Shoji; Yoichi Nakazato
Journal:  Brain Res       Date:  2008-03-08       Impact factor: 3.252

6.  Presence of reactive microglia and neuroinflammatory mediators in a case of frontotemporal dementia with P301S mutation.

Authors:  Arianna Bellucci; Orso Bugiani; Bernardino Ghetti; Maria Grazia Spillantini
Journal:  Neurodegener Dis       Date:  2011-01-05       Impact factor: 2.977

7.  Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease.

Authors:  Adam C Naj; Gyungah Jun; Gary W Beecham; Li-San Wang; Badri Narayan Vardarajan; Jacqueline Buros; Paul J Gallins; Joseph D Buxbaum; Gail P Jarvik; Paul K Crane; Eric B Larson; Thomas D Bird; Bradley F Boeve; Neill R Graff-Radford; Philip L De Jager; Denis Evans; Julie A Schneider; Minerva M Carrasquillo; Nilufer Ertekin-Taner; Steven G Younkin; Carlos Cruchaga; John S K Kauwe; Petra Nowotny; Patricia Kramer; John Hardy; Matthew J Huentelman; Amanda J Myers; Michael M Barmada; F Yesim Demirci; Clinton T Baldwin; Robert C Green; Ekaterina Rogaeva; Peter St George-Hyslop; Steven E Arnold; Robert Barber; Thomas Beach; Eileen H Bigio; James D Bowen; Adam Boxer; James R Burke; Nigel J Cairns; Chris S Carlson; Regina M Carney; Steven L Carroll; Helena C Chui; David G Clark; Jason Corneveaux; Carl W Cotman; Jeffrey L Cummings; Charles DeCarli; Steven T DeKosky; Ramon Diaz-Arrastia; Malcolm Dick; Dennis W Dickson; William G Ellis; Kelley M Faber; Kenneth B Fallon; Martin R Farlow; Steven Ferris; Matthew P Frosch; Douglas R Galasko; Mary Ganguli; Marla Gearing; Daniel H Geschwind; Bernardino Ghetti; John R Gilbert; Sid Gilman; Bruno Giordani; Jonathan D Glass; John H Growdon; Ronald L Hamilton; Lindy E Harrell; Elizabeth Head; Lawrence S Honig; Christine M Hulette; Bradley T Hyman; Gregory A Jicha; Lee-Way Jin; Nancy Johnson; Jason Karlawish; Anna Karydas; Jeffrey A Kaye; Ronald Kim; Edward H Koo; Neil W Kowall; James J Lah; Allan I Levey; Andrew P Lieberman; Oscar L Lopez; Wendy J Mack; Daniel C Marson; Frank Martiniuk; Deborah C Mash; Eliezer Masliah; Wayne C McCormick; Susan M McCurry; Andrew N McDavid; Ann C McKee; Marsel Mesulam; Bruce L Miller; Carol A Miller; Joshua W Miller; Joseph E Parisi; Daniel P Perl; Elaine Peskind; Ronald C Petersen; Wayne W Poon; Joseph F Quinn; Ruchita A Rajbhandary; Murray Raskind; Barry Reisberg; John M Ringman; Erik D Roberson; Roger N Rosenberg; Mary Sano; Lon S Schneider; William Seeley; Michael L Shelanski; Michael A Slifer; Charles D Smith; Joshua A Sonnen; Salvatore Spina; Robert A Stern; Rudolph E Tanzi; John Q Trojanowski; Juan C Troncoso; Vivianna M Van Deerlin; Harry V Vinters; Jean Paul Vonsattel; Sandra Weintraub; Kathleen A Welsh-Bohmer; Jennifer Williamson; Randall L Woltjer; Laura B Cantwell; Beth A Dombroski; Duane Beekly; Kathryn L Lunetta; Eden R Martin; M Ilyas Kamboh; Andrew J Saykin; Eric M Reiman; David A Bennett; John C Morris; Thomas J Montine; Alison M Goate; Deborah Blacker; Debby W Tsuang; Hakon Hakonarson; Walter A Kukull; Tatiana M Foroud; Jonathan L Haines; Richard Mayeux; Margaret A Pericak-Vance; Lindsay A Farrer; Gerard D Schellenberg
Journal:  Nat Genet       Date:  2011-04-03       Impact factor: 38.330

8.  Trans-synaptic spread of tau pathology in vivo.

Authors:  Li Liu; Valerie Drouet; Jessica W Wu; Menno P Witter; Scott A Small; Catherine Clelland; Karen Duff
Journal:  PLoS One       Date:  2012-02-01       Impact factor: 3.240

9.  Interleukin-1 receptor antagonist penetrates human brain at experimentally therapeutic concentrations.

Authors:  Simon R Clark; Catherine J McMahon; Iva Gueorguieva; Malcolm Rowland; Sylvia Scarth; Rachel Georgiou; Pippa J Tyrrell; Stephen J Hopkins; Nancy J Rothwell
Journal:  J Cereb Blood Flow Metab       Date:  2007-08-08       Impact factor: 6.200

10.  What is the Most Sensitive Measure of Water Maze Probe Test Performance?

Authors:  Hamid R Maei; Kirill Zaslavsky; Cátia M Teixeira; Paul W Frankland
Journal:  Front Integr Neurosci       Date:  2009-03-09
View more
  178 in total

Review 1.  Inflammation in Alzheimer's disease: Lessons learned from microglia-depletion models.

Authors:  Elizabeth E Spangenberg; Kim N Green
Journal:  Brain Behav Immun       Date:  2016-07-06       Impact factor: 7.217

Review 2.  Innate immune activation in Alzheimer's disease.

Authors:  Ming-Ming Wang; Dan Miao; Xi-Peng Cao; Lin Tan; Lan Tan
Journal:  Ann Transl Med       Date:  2018-05

3.  Functional connectivity associated with tau levels in ageing, Alzheimer's, and small vessel disease.

Authors:  Nicolai Franzmeier; Anna Rubinski; Julia Neitzel; Yeshin Kim; Alexander Damm; Duk L Na; Hee Jin Kim; Chul Hyoung Lyoo; Hana Cho; Sofia Finsterwalder; Marco Duering; Sang Won Seo; Michael Ewers
Journal:  Brain       Date:  2019-04-01       Impact factor: 13.501

4.  Opposing effects of progranulin deficiency on amyloid and tau pathologies via microglial TYROBP network.

Authors:  Hideyuki Takahashi; Zoe A Klein; Sarah M Bhagat; Adam C Kaufman; Mikhail A Kostylev; Tsuneya Ikezu; Stephen M Strittmatter
Journal:  Acta Neuropathol       Date:  2017-01-09       Impact factor: 17.088

5.  Acid Sphingomyelinase Inhibition Mitigates Histopathological and Behavioral Changes in a Murine Model of Traumatic Brain Injury.

Authors:  Grace M Niziolek; Ryan M Boudreau; Jennifer Baker; Lou Ann Friend; Amy T Makley; Michael J Edwards; Erich Gulbins; Michael D Goodman
Journal:  J Neurotrauma       Date:  2020-05-04       Impact factor: 5.269

6.  Reduced gliotransmitter release from astrocytes mediates tau-induced synaptic dysfunction in cultured hippocampal neurons.

Authors:  Roberto Piacentini; Domenica Donatella Li Puma; Marco Mainardi; Giacomo Lazzarino; Barbara Tavazzi; Ottavio Arancio; Claudio Grassi
Journal:  Glia       Date:  2017-05-18       Impact factor: 7.452

7.  SIRT1 Deacetylates Tau and Reduces Pathogenic Tau Spread in a Mouse Model of Tauopathy.

Authors:  Sang-Won Min; Peter Dongmin Sohn; Yaqiao Li; Nino Devidze; Jeffrey R Johnson; Nevan J Krogan; Eliezer Masliah; Sue-Ann Mok; Jason E Gestwicki; Li Gan
Journal:  J Neurosci       Date:  2018-03-14       Impact factor: 6.167

Review 8.  Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight.

Authors:  Yang Shi; David M Holtzman
Journal:  Nat Rev Immunol       Date:  2018-12       Impact factor: 53.106

Review 9.  Chronic traumatic encephalopathy-integration of canonical traumatic brain injury secondary injury mechanisms with tau pathology.

Authors:  Jacqueline R Kulbe; Edward D Hall
Journal:  Prog Neurobiol       Date:  2017-08-26       Impact factor: 11.685

10.  Traumatic Brain Injury in hTau Model Mice: Enhanced Acute Macrophage Response and Altered Long-Term Recovery.

Authors:  Olga N Kokiko-Cochran; Maha Saber; Shweta Puntambekar; Shane M Bemiller; Atsuko Katsumoto; Yu-Shang Lee; Kiran Bhaskar; Richard M Ransohoff; Bruce T Lamb
Journal:  J Neurotrauma       Date:  2017-11-01       Impact factor: 5.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.